TLRY
TLRY
NASDAQ · Pharmaceuticals

Tilray Brands Inc

$6.45
+0.24 (+3.86%)
As of Mar 23, 10:04 PM ET ·
Financial Highlights (FY 2026)
Revenue
103.89M
Net Income
-276,600,363
Gross Margin
29.3%
Profit Margin
-266.3%
Rev Growth
+9.3%
D/E Ratio
0.20
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 29.3% 29.3% 58.9% 58.9%
Operating Margin -277.9% -250.1% 36.6% 37.4%
Profit Margin -266.3% -252.9% 27.4% 25.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 103.89M 95.02M 180.40M 169.99M
Gross Profit 30.43M 27.83M 106.25M 100.12M
Operating Income -288,741,029 -237,668,672 66.09M 63.51M
Net Income -276,600,363 -227,675,440 49.45M 42.44M
Gross Margin 29.3% 29.3% 58.9% 58.9%
Operating Margin -277.9% -250.1% 36.6% 37.4%
Profit Margin -266.3% -252.9% 27.4% 25.0%
Rev Growth +9.3% +9.3% -1.4% +19.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 64.74M 64.74M 368.43M 383.92M
Total Equity 323.23M 323.23M 614.67M 608.97M
D/E Ratio 0.20 0.20 0.60 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -274,010,156 -238,073,576 94.91M 94.57M
Free Cash Flow 60.57M 46.11M